THERAPEUTIC ANTIBODIES

Transcription

1 Spring Meeting of the Swiss Society of Pharmacology and Toxicology THERAPEUTIC ANTIBODIES THE GOOD, THE BAD, AND THE UGLY April 19, 2018, Inselspital Bern Source: Aldona von Gunten 1

2 SSPT Spring Meeting 2018 Auditorium Langhans, Inselspital Bern April 19, 2018 Organizing Team: Support: Thierry Buclin, University Hospital (CHUV) of Lausanne / Stephan von Gunten, University of Bern/ Hugo Kupferschmidt, Tox Info Suisse Zürich / Elisabeth Rosner, Novartis Basel / Martin Traber, Roche Basel / Thomas Weiser, Roche Basel /Gabriele Weitz-Schmidt, AlloCyte Basel Interpharma, ImmuPhar, Swiss Industry Science Fund (SISF), SAMW, Life Science Switzerland LS2; deficit guarantee by SCNAT Deadlines: Abstract submission and registration deadline: April 3, 2018 Program Registration and poster set-up 08:00-09:00 Session I 09:00-10:10 Chairs: Martin Traber, Roche (Basel) & Manuel Haschke, Inselspital (Bern) 09:00-09:10 Welcome address Martin Traber, Roche Basel, President of the SSPT 09:10-09:30 PD1/PD1L immune check point inhibition Alfred Zippelius, University Hospital Basel 09:30-09:50 Clinical experience with checkpoint inhibitors: benefit/risk ratio in the real world Olivier Michielin, University Hospital (CHUV) of Lausanne 09:50-10:10 Antibody-cytokine fusion proteins: from the bench to Phase III clinical trials Dario Neri, ETH Zürich Coffee break and poster viewing 10:10-10:40 2

3 Session II 10:40-12:10 Chairs: Thierry Buclin, CHUV (Lausanne) & Thomas Weiser, Roche (Basel) 10:40-11:00 Skin inflammation: Fascinating window to observe biologics in action Alexander Navarini, University of Zürich IUPHAR lecture 11:00-11:20 Development of anti-inflammatory drugs: Targeting selectins and leukocyte trafficking Richard D. Cummings, Harvard Medical School, Boston 11:20-11:40 First in human strategies with biotherapeutics using surrogate and/or in vitro -only approaches Roche case studies Anneliese Schneider, Roche Basel Rapid fire presentations (preclinical/clinical) 11:40-11:45 Myoblasts versus myotubes: Mechanisms of toxicity in the context of simvastatin treatment Gerda M Sanvee, University Hospital Basel 11:45-11:50 Downregulation of intratumoral HMGB1 reduces tumor growth by an immune-mediated mechanism Betül Taşkoparan, University of Geneva 11:50-11:55 Validation of novel fingolimod derivatives for EAE therapy Bisera Stepanovska, University of Bern 11:55-12:00 Pharmacokinetics of ivermectin in microsamples of three healthy volunteers Urs Duthaler, University Hospital Basel 12:00-12:05 Immune checkpoint inhibitor cardiac toxicity: Analysis of WHO international global database of suspected adverse drug reactions R. Noseda, Ente Ospedaliero Cantonale, Institute of Pharmacological Sciences of Southern Switzerland 12:05-12:10 Ocular injuries from head lice shampoos based on mineral oils in combination with detergents, a consecutive case series KE Hofer, National Poisons Centre, Tox Info Suisse, Associated Institute of the University of Zurich 3

4 Poster session and buffet lunch 12:10-13:45 12:30-13:00 poster 1-15 / 13:00-13:30 - poster 15f Session III 13:45-15:05 Chair: Hugo Kupferschmidt, Tox Info Suisse (Zürich) & Hans-Uwe Simon, University of Bern 13:45-14:05 Fab antibody fragments for the treatment of colchicine toxicity Michael Eddleston, University of Edinburgh 14:05-14:25 B cell depletion in multiple sclerosis: Mechanisms and clinical efficacy Jan Lünemann, University of Zürich 14:25-14:45 Therapeutic potential of intravenous immunoglobulin (IVIG) and other polyclonal antibodies Stephan von Gunten, University of Bern 14:45-15:05 Human IgA bind a diverse array of commensal bacteria Guy Gorochov, Hôpital Pitié-Salpêtrière, Paris Coffee Break 15:05-15:30 Session IV 15:30-16:45 Chairs: Stephan von Gunten, University of Bern & Gabriele Weitz-Schmidt, AlloCyte (Basel) Young investigator presentations 15:30-15:45 Glycan-Checkpoint Inhibitor unleashing CD8+ T cells against Cancer Quentin Haas, University of Bern 15:45-16:00 Autoimmune Adverse Drug Reactions to Checkpoint Inhibitors P. Frei, University Hospital Basel 16:00-16:15 Crossmodulation of integrins by monoclonal antibodies targeting the integrin αlβ2 Riccardo Mancuso, University Hospital Basel 4

5 Keynote lecture 16:15-16:45 Monoclonal antibodies for infectious diseases Antonio Lanzavecchia, Institute for Research in Biomedicine, Bellinzona Bürgi Prize for best PhD thesis: Lecture & Award 16:45-17:00 Novartis Prize for best poster and best young investigator presentation 17:00-17:10 Concluding remarks and end of meeting 17:10-17:15 17:30-18:30 SSEP General Assembly: SSEP members only - Seminar room PKI 17:30-18:30 SSCPT General Assembly: SSCPT members only - Auditorium Langhans 5